Evonik has partnered with ST Pharm, a CDMO based in South Korea that manufactures active ingredients for gene therapy, to expand its RNA and nucleic acid therapeutic services. Through the partnership, Evonik will be able to provide customized nucleic acids from ST Pharm alongside its portfolio of lipid and lipid nanoparticle (LNP) drug product development services. This streamlined approach aims to reduce complexity and increase speed-to-market for nucleic acid therapeutics.

“Speed is critical in drug development, and this partnership helps to streamline the process and offer system solutions. We look forward to supporting our customers in developing the nucleic-acid therapeutics of the future,” said Yann d’Hervé, Head of Evonik’s Health Care business line.

“Partnering with Evonik, which has Drug Product manufacturing facilities in North America, allows us to expand into the global mRNA market while strengthening existing customer relationships,” said Kris S. Choi, Head of Marketing & BD at ST Pharm. “Our mRNA development expertise, including SmartCap technology, aligns seamlessly with Evonik’s LNP and Fill & Finish capabilities.”